Would you guess that Elon Musk might be into using biotechnology in a high-profile way to try to live far longer than usual, say to age 150? That would have been my assumption. There are countless things about Elon Musk that I really don’t like. I also don’t see many issues on which we are …
I found something Elon Musk & I agree on: pushing back on anti-aging bluster Read More »
Readers of The Niche have asked me many questions about stem cells for autoimmune disease but the puzzle of why women get these conditions more often than men hasn’t come up before here. For instance, why is MS so much more common in women than men? It’s remained somewhat of a mystery over the years. …
The biotechs Vertex and CRISPR Therapeutics have an interesting relationship as biotechs. They are partners are multiple levels but also are very different as companies including in size. There’s been a key development in one of their partnerships. Before we jump into that, please check out the video version of my 20 stem cell and …
Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics Read More »
Let’s start this week’s digest with a discussion of clonal expansion and mutations during cell and gene therapy development. Here’s the article that brought this to mind. Sickle cell gene therapy process may cause cancer-linked mutations in blood stem cells, Fierce Biotech. Clonal expansion This is a story about a non-CRISPR gene therapy using a …
Some folks can view data from early, small clinical trials too skeptically or overly enthusiastically, and maybe that’s going on with some preliminary results from Verve Therapeutics. Good news? Bad news? I’m going to start with two articles about the same news that have very different vibes. What do I think? On the whole, I …
Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC Read More »
For me, this was another week of heavy grant writing but also taking on Google again. How? Over how badly its search engine often performs on stem cell queries. I have a new piece at MedPage Today. It’s focused on the problem of Google Search promoting unproven stem cell clinic websites. Google still prefers stem …
Weekly reads: Google, CIRM, young Swedish bone marrow Read More »
What’s more important than Woolly Mammoth de-extinction research in the stem cell arena? Only maybe a 10,000 other things. Still, the mammoth de-extinction efforts capture people’s attention much more than the average research story. Mammoth De-extinction update Is de-extinction only a pipette dream? This startup has a big, expensive plan to find out, Popular Science. …
A days ago the news came about Mesoblast not getting FDA approval for its MSC product for GvHD. The MSC area has had a rough few years with various clinical trials including for COVID. The “stem cells for heart disease” arena has also had a tough time. Here’s more news along these lines: BioCardia pauses enrollment in PhIII trial …
Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA Read More »
Altos Labs is an intriguing multi-institution experiment in so-called rejuvenation research all rolled into one biotech. This relatively new entity headquartered in California has multiple Nobel laureates in the biomedical field in leadership. Even more importantly it has a large group of great researchers leading its individual research labs. This all leads to high expectations, …
Some surprises from new analysis of Altos Labs papers Read More »
The Bay Area biotech Conception Bio has an intriguing name. What does “conception” mean here? Scientists can make many things from stem cells. For example, lately I’ve written a lot about stem cell-based human embryo models. Another intriguing area is called in vitro gametogenesis or IVG, where Conception Bio is a leader. IVG means making …
Weekly reads: Conception Bio & IVG, MYC, Stanford Prez resigns Read More »